EUVIMEDEUVIMED entdecken
Crossref

A Seamless Two‐Stage Phase I/ II Trial Design With Backfill and Joint Monitoring for Dose Optimization

Kentaro Takeda iD, Jing Zhu, Belay B Yimer iD, Akihiro Hirakawa iD

Pharmaceutical Statistics · 2026-05 · 25 (3)

DOI: 10.1002/pst.70092 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, online erschienen am 19.04.2026. Verfasst von Kentaro Takeda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Astellas Pharma Global Development Inc., Northbrook, Illinois, USA. Hauptthemen laut MEDLINE: Research Design, Clinical Trials, Phase I as Topic, Antineoplastic Agents, Clinical Trials, Phase II as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA's Project Optimus initiative emphasizes dose optimization through randomized cohorts and comprehensive evaluation across dose levels. Additionally, early‐phase oncology trials must efficiently evaluate antitumor activity while maintaining patient safety, requiring robust statistical frameworks for futility monitoring. We propose a seamless two‐stage Phase I/II trial design integrating dose optimization with efficacy evaluation. Stage 1 employs a dose‐finding approach with patient backfilling, utilizing Bayesian optimal boundaries for efficacy and toxicity to select two promising doses for further evaluation. The backfill strategy enables sequential enrollment while previous patients continue their evaluation periods, thereby accelerating the trial. Stage 2 simultaneously identifies the optimal dose and evaluates treatment effectiveness through joint monitoring of efficacy and toxicity outcomes. Stage 2 incorporates Bayesian optimal boundaries for both futility and efficacy stopping, enabling early decision‐making while explicitly controlling Type I error rates. Simulation studies across realistic scenarios demonstrate superior operating characteristics of the proposed design compared to existing designs, making this approach particularly valuable for modern oncology drug development where efficiency, accuracy, and patient safety are paramount.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignClinical Trials, Phase I as TopicAntineoplastic AgentsClinical Trials, Phase II as TopicHumansBayes TheoremDose-Response Relationship, DrugComputer Simulation

Stichwörter der Autor:innen

backfilldose optimizationjoint monitoringmodel‐assisted designstopping boundaries

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Astellas Pharma Global Development Inc., Northbrook, Illinois, USA.
  • Astellas Pharma China, Beijing, China.
  • Astellas Pharma Europe Ltd., Addlestone, UK.
  • Institute of Science Tokyo, Tokyo, Japan.

ORCID-Profile: Kentaro Takeda, Belay B Yimer, Akihiro Hirakawa

Zitieren

APA

Takeda, K., Zhu, J., Yimer, B. B., & Hirakawa, A. (2026). A Seamless Two‐Stage Phase I/ II Trial Design With Backfill and Joint Monitoring for Dose Optimization. Pharmaceutical Statistics, 25(3). https://doi.org/10.1002/pst.70092

Vancouver

Takeda K, Zhu J, Yimer BB, Hirakawa A. A Seamless Two‐Stage Phase I/ II Trial Design With Backfill and Joint Monitoring for Dose Optimization. Pharmaceutical Statistics. 2026;25(3). doi:10.1002/pst.70092

BibTeX
@article{Takeda2026,
  author = {Takeda, Kentaro and Zhu, Jing and Yimer, Belay B and Hirakawa, Akihiro},
  title = {A Seamless Two‐Stage Phase I/ II Trial Design With Backfill and Joint Monitoring for Dose Optimization},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  volume = {25},
  number = {3},
  doi = {10.1002/pst.70092}
}
Kostenlos starten →